DV
Dividend Vision

CARM — Carisma Therapeutics Inc.

Carisma Therapeutics Inc. (CARM)

Its deepest 1-year drawdown was 100.0%.

Carisma Therapeutics is a biotechnology company developing cell therapy treatments for liver fibrosis and cancer, with product candidates including CT-2401 for liver fibrosis in preclinical testing and CT-1119, a CAR-monocyte therapy in phase I trials for mesothelin-positive solid tumors such as pancreatic, ovarian, and lung cancers. The company does not currently distribute dividends. Carisma appeals to investors seeking exposure to early-stage biotechnology development rather than current income generation.

CARM key facts

Asset type
Stock
Asset class
Equity
Inception date
02/06/2014
Last close
$0.0022
Market cap
$217,594
Average volume
2251.0
Last dividend
$0.0181
Payment date
03/08/2023
Payout ratio
0.0
P/E ratio
0.0274
Forward P/E
0.0
EPS
$0.19